bevacizumab + leucovorin + uracil-tegafur

Bevacizumab combined with oral leucovorin and uracil-tegafur (UFT) is a combination chemotherapy regimen primarily used for the treatment of metastatic colorectal cancer, especially in elderly patients aged 75 years or older. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis which tumors require for growth. Uracil-tegafur is an oral prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that interferes with DNA synthesis, and leucovorin enhances the efficacy of 5-FU by stabilizing its binding to thymidylate synthase. This combination has demonstrated tolerability and effectiveness as first-line therapy in elderly patients with advanced or metastatic colorectal cancer, showing median progression-free survival around 8-9 months and overall survival approximately 18-22 months in clinical studies. The regimen offers an oral chemotherapy option combined with targeted therapy via bevacizumab infusion[1][2][3].

Other names

Bmab + UFT/LVUFT/LV plus bevacizumab